Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Brimonidine Tartrate (Alias: UK14304 tartrate, UK 14304 (tartrate), AGN190342 tartrate, AGN190342 (tartrat...)

Catalog No. T6422 Copy Product Info
Purity: 99.95%
🥰Excellent
Brimonidine Tartrate (AGN190342 tartrate) is a quinoxaline derivative and adrenergic α-2 receptor agonist (EC50: 0.45 nM) that is used to manage intraocular pressure associated with open-angle glaucoma or ocular hypertension.

Brimonidine Tartrate

Copy Product Info
🥰Excellent
Catalog No. T6422
Alias UK14304 tartrate, UK 14304 (tartrate), AGN190342 tartrate, AGN190342 (tartrate)

Brimonidine Tartrate (AGN190342 tartrate) is a quinoxaline derivative and adrenergic α-2 receptor agonist (EC50: 0.45 nM) that is used to manage intraocular pressure associated with open-angle glaucoma or ocular hypertension.

Brimonidine Tartrate
Cas No. 70359-46-5
Pack SizePriceUSA StockGlobal StockQuantity
100 mg$41In StockIn Stock
500 mg$126-In Stock
In stock · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:99.95%
Appearance:Solid
Color:White
Contact us for more batch information

Resource Download

Product Introduction

Brimonidine Tartrate AI Summary
Brimonidine Tartrate exhibits a diverse range of bioactivities and effects across different biological assays and cell types. In Vero E6 cells infected with SARS-CoV-2 (strain BavPat1), it shows low inhibitory activity on cell viability, with an inhibition index of 0.355 after 72 hours. The compound also exhibits varied impacts on cell growth rates in Incucyte cell viability assays with HEK293T, U2OS, and human fibroblast cells, with growth rates ranging from 0.29 to 0.95, indicating cell-type-specific effects on viability and proliferation. Thermal shift assay results reveal that Brimonidine Tartrate can both stabilize and destabilize various protein domains, affecting their Delta TM values and suggesting complex interactions with different protein regions. Additionally, Brimonidine Tartrate modulates activity in GPCR beta-arrestin recruitment assays, displaying both stimulatory and inhibitory effects across different targets, indicating potential for diverse pharmacological applications..
Note: Summary generated by AI. Data source: ChEMBL
Bioactivity
Description
Brimonidine Tartrate (AGN190342 tartrate) is a quinoxaline derivative and adrenergic α-2 receptor agonist (EC50: 0.45 nM) that is used to manage intraocular pressure associated with open-angle glaucoma or ocular hypertension.
Targets&IC50
α2A-adrenoceptor:0.45 nM(EC50)
In vitro
Brimonidine (0.5/1 mg/kg) reduced progressive ganglion cell loss (26%/15%). At elevated intraocular pressure, the use of Brimonidine significantly protected retinal ganglion cells and prevented further cell loss. Brimonidine injection into the eyes of SD rats increased the number of brain-derived neurotrophic factor-positive retinal ganglion cells from 55% to 166%. Brimonidine prevented further ganglion cell loss after 10 days of elevated IOP.Brimonidine increased immunoreactivity for glial fibrillary acidic protein in the hypertensive retina of attenuated eyes.
In vivo
Brimonidine (0.5/1 mg/kg) reduced progressive ganglion cell loss (26%/15%). At elevated intraocular pressure, the use of Brimonidine significantly protected retinal ganglion cells and prevented further cell loss. Brimonidine injection into the eyes of SD rats increased the number of brain-derived neurotrophic factor-positive retinal ganglion cells from 55% to 166%. Brimonidine prevented further ganglion cell loss after 10 days of elevated IOP.Brimonidine increased immunoreactivity for glial fibrillary acidic protein in the hypertensive retina of attenuated eyes.
SynonymsUK14304 tartrate, UK 14304 (tartrate), AGN190342 tartrate, AGN190342 (tartrate)
Chemical Properties
Molecular Weight442.22
FormulaC15H16BrN5O6
Cas No.70359-46-5
SmilesO[C@H]([C@@H](O)C(O)=O)C(O)=O.Brc1c(NC2=NCCN2)ccc2nccnc12
Relative Density.no data available
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
Solubility Information
DMSO: 16.67 mg/mL (37.7 mM), Sonication is recommended.
H2O: 56.53 mM, Sonication is recommended.
In Vivo Formulation
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.52 mM), Sonication is recommended.
Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.
Solution Preparation Table
DMSO/H2O
1mg5mg10mg50mg
1 mM2.2613 mL11.3066 mL22.6132 mL113.0659 mL
5 mM0.4523 mL2.2613 mL4.5226 mL22.6132 mL
10 mM0.2261 mL1.1307 mL2.2613 mL11.3066 mL
20 mM0.1131 mL0.5653 mL1.1307 mL5.6533 mL
H2O
1mg5mg10mg50mg
50 mM0.0452 mL0.2261 mL0.4523 mL2.2613 mL
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy Brimonidine Tartrate | purchase Brimonidine Tartrate | Brimonidine Tartrate cost | order Brimonidine Tartrate | Brimonidine Tartrate chemical structure | Brimonidine Tartrate in vivo | Brimonidine Tartrate in vitro | Brimonidine Tartrate formula | Brimonidine Tartrate molecular weight